Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.330
Open
2.230
VWAP
2.28
Vol
876.98K
Mkt Cap
244.53M
Low
2.230
Amount
2.00M
EV/EBITDA(TTM)
--
Total Shares
104.54M
EV
98.82M
EV/OCF(TTM)
--
P/S(TTM)
6.23
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The Company has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx, GTx and VLx. Its ATx static electroporation instrument is research focused, performance electroporation platform for small to medium scale transfection. Its STx is used in the field of protein production.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
10.93M
+25.72%
-0.080
-20%
10.46M
+28.06%
-0.087
-21.21%
9.57M
-8.25%
-0.103
+14.81%
Estimates Revision
The market is revising Downward the revenue expectations for MaxCyte, Inc. (MXCT) for FY2025, with the revenue forecasts being adjusted by -11% over the past three months. During the same period, the stock price has changed by -42.79%.
Revenue Estimates for FY2025
Revise Downward
-11%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-10.43%
In Past 3 Month
Stock Price
Go Down
-42.79%
In Past 3 Month
5 Analyst Rating
226.09% Upside
Wall Street analysts forecast MXCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MXCT is 7.50 USD with a low forecast of 6.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
226.09% Upside
Current: 2.300
Low
6.00
Averages
7.50
High
9.00
226.09% Upside
Current: 2.300
Low
6.00
Averages
7.50
High
9.00
Stifel
Daniel Arias
Strong Buy
Maintains
$11 → $9
2025-03-12
Reason
Stifel
Daniel Arias
Price Target
$11 → $9
2025-03-12
Maintains
Strong Buy
Reason
Stifel lowered the firm's price target on MaxCyte to $9 from $11 and keeps a Buy rating on the shares. Management's guidance for 2025 positions core revenues as up 8%-15%, notes the analyst, who adds that there "does appear to be upside potential to the guide," most notably from an embedded assumption that end markets do not improve. The firm continues to like MaxCyte as a play on what should be a rebound year for cell therapy, but "the pace at which the thesis plays out could be on the slower side," the analyst added.
See All Ratings
Valuation Metrics
The current forward P/E ratio for MaxCyte Inc (MXCT.O) is -5.95, compared to its 5-year average forward P/E of -18.30. For a more detailed relative valuation and DCF analysis to assess MaxCyte Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-18.30
Current PE
-5.95
Overvalued PE
-2.17
Undervalued PE
-34.43
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-19.05
Current EV/EBITDA
-2.96
Overvalued EV/EBITDA
6.78
Undervalued EV/EBITDA
-44.87
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
13.53
Current PS
5.37
Overvalued PS
21.38
Undervalued PS
5.69
Financials
Annual
Quarterly
FY2025Q1
YoY :
-8.39%
10.39M
Total Revenue
FY2025Q1
YoY :
+0.16%
-12.30M
Operating Profit
FY2025Q1
YoY :
-100.00%
N/A
Net Income after Tax
FY2025Q1
YoY :
-100.00%
N/A
EPS - Diluted
FY2025Q1
YoY :
+32.51%
-15.06M
Free Cash Flow
FY2025Q1
YoY :
-3.62%
75.38
Gross Profit Margin - %
FY2025Q1
YoY :
+24.83%
-87.48
FCF Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
27.0K
USD
3
3-6
Months
57.6K
USD
5
6-9
Months
570.4K
USD
7
0-12
Months
323.6K
USD
5
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
2
489.1K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
172.5K
Volume
2
Bought
0-3
0
0.0
Volume
Months
3-6
1
1.2M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
2
2.1M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
27.0K
USD
3
3-6
Months
57.6K
USD
5
6-9
Months
570.4K
USD
7
0-12
Months
323.6K
USD
5
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
2
489.1K
USD
Months
MXCT News & Events
Events Timeline
2025-05-07 (ET)
2025-05-07
16:34:45
MaxCyte reports Q1 EPS (10c), consensus (10c)
2025-03-11 (ET)
2025-03-11
16:14:58
MaxCyte sees FY25 core business revenue up 8%-15%
2025-03-11
16:14:13
MaxCyte reports Q4 EPS (10c), consensus (12c)
Sign Up For More Events
Sign Up For More Events
News
9.5
05-07NewsfilterMaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
9.5
04-10Yahoo FinanceMaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
2.0
03-12BenzingaHello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Sign Up For More News
People Also Watch
SBC
SBC Medical Group Holdings Inc
3.400
USD
-2.30%
FLWS
1-800-Flowers.Com Inc
4.650
USD
-2.11%
SHBI
Shore Bancshares Inc
14.840
USD
-1.46%
HKD
AMTD Digital Inc
2.130
USD
+1.72%
FFWM
First Foundation Inc
5.280
USD
-1.12%
MATV
Mativ Holdings Inc
6.070
USD
+1.51%
DDI
DoubleDown Interactive Co Ltd
10.050
USD
-0.99%
PSBD
Palmer Square Capital BDC Inc
13.830
USD
+0.22%
VERV
Verve Therapeutics Inc
4.630
USD
+7.18%
UHT
Universal Health Realty Income Trust
39.590
USD
+0.76%
FAQ
What is MaxCyte Inc (MXCT) stock price today?
The current price of MXCT is 2.3 USD — it has increased 3.14 % in the last trading day.
What is MaxCyte Inc (MXCT)'s business?
What is the price predicton of MXCT Stock?
What is MaxCyte Inc (MXCT)'s revenue for the last quarter?
What is MaxCyte Inc (MXCT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for MaxCyte Inc (MXCT)'s fundamentals?
How many employees does MaxCyte Inc (MXCT). have?